Cargando…

Gene Expression Analysis in Ovarian Cancer – Faults and Hints from DNA Microarray Study

The introduction of microarray techniques to cancer research brought great expectations for finding biomarkers that would improve patients’ treatment; however, the results of such studies are poorly reproducible and critical analyses of these methods are rare. In this study, we examined global gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lisowska, Katarzyna Marta, Olbryt, Magdalena, Dudaladava, Volha, Pamuła-Piłat, Jolanta, Kujawa, Katarzyna, Grzybowska, Ewa, Jarząb, Michał, Student, Sebastian, Rzepecka, Iwona Krystyna, Jarząb, Barbara, Kupryjańczyk, Jolanta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904181/ https://www.ncbi.nlm.nih.gov/pubmed/24478986 http://dx.doi.org/10.3389/fonc.2014.00006

Ejemplares similares

Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report
por: Dudaladava, Volha, et al.
Publicado: (2006)

Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival
por: Lisowska, Katarzyna M., et al.
Publicado: (2016)

Global Gene Expression Profiling in Three Tumor Cell Lines Subjected to Experimental Cycling and Chronic Hypoxia
por: Olbryt, Magdalena, et al.
Publicado: (2014)

The putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients
por: Szafron, Lukasz Michal, et al.
Publicado: (2015)

Gene expression signature of hereditary breast cancer
por: Dudaladava, V, et al.
Publicado: (2005)

Fibronectin and Periostin as Prognostic Markers in Ovarian Cancer
por: Kujawa, Katarzyna Aleksandra, et al.
Publicado: (2020)

Genetic 3′UTR variations and clinical factors significantly contribute to survival prediction and clinical response in breast cancer patients
por: Pamuła-Piłat, Jolanta, et al.
Publicado: (2020)

Copper transport system and response to ovarian cancer chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Pharmacogenetics of FAC chemotherapy side effects in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2015)

Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2016)

Microfibril Associated Protein 5 (MFAP5) Is Related to Survival of Ovarian Cancer Patients but Not Useful as a Prognostic Biomarker
por: Kujawa, Katarzyna Aleksandra, et al.
Publicado: (2022)

Comparison of the expression profile in breast cancer and ovarian cancer
por: Jarzab, M, et al.
Publicado: (2005)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Genetic polymorphisms, efficiency and toxicity of cancer chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2018)

Clinicopathological characteristics of breast cancer patients with NOD2 mutation according to age
por: Huszno, Joanna, et al.
Publicado: (2020)

Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
por: Rusinek, Dagmara, et al.
Publicado: (2017)

High-throughput genotyping of a common deletion polymorphism disrupting the TRY6 gene and its association with breast cancer risk
por: Wagner, Kerstin, et al.
Publicado: (2007)

Evaluation of the Role of ITGBL1 in Ovarian Cancer
por: Cortez, Alexander Jorge, et al.
Publicado: (2020)

Concentrations of Selected Adipokines, Interleukin-6, and Vitamin D in Patients with Papillary Thyroid Carcinoma in Respect to Thyroid Cancer Stages
por: Warakomski, Jakub, et al.
Publicado: (2018)

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
por: Kukulska, Aleksandra, et al.
Publicado: (2010)

Liposome-based DNA carriers may induce cellular stress response and change gene expression pattern in transfected cells
por: Fiszer-Kierzkowska, Anna, et al.
Publicado: (2011)

Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland
por: Pamuła, Jolanta, et al.
Publicado: (2006)

Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma
por: Krajewska, Jolanta, et al.
Publicado: (2019)

Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma—Do They Exist?
por: Szpak-Ulczok, Sylwia, et al.
Publicado: (2020)

Spectrum of tumors in the families with Hereditary Breast Ovarian Cancer syndrome carrying germline mutations in BRCA1 and 2 genes
por: Budryk, M, et al.
Publicado: (2012)

Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8
por: Tudrej, Patrycja, et al.
Publicado: (2018)

Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients
por: Felisiak-Golabek, Anna, et al.
Publicado: (2011)

BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma
por: Rusinek, Dagmara, et al.
Publicado: (2015)

Lobo-isthmectomy in the management of differentiated thyroid cancer
por: Krajewska, Jolanta, et al.
Publicado: (2023)

Transcriptional profiles of pilocytic astrocytoma are related to their three different locations, but not to radiological tumor features
por: Zakrzewski, Krzysztof, et al.
Publicado: (2015)

Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers – the role of Ct serum level
por: Jarzab, Barbara, et al.
Publicado: (2013)

Current status of the prognostic molecular markers in medullary thyroid carcinoma
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2020)

Prognostic value of lymph node metastases of differentiated thyroid cancer (DTC) according to the local advancement and range of surgical excision
por: Czarniecka, Agnieszka, et al.
Publicado: (2010)

The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAF(V600E) Mutation Status and Other Prognostic Factors
por: Czarniecka, Agnieszka, et al.
Publicado: (2015)

HAX-1 overexpression, splicing and cellular localization in tumors
por: Trebinska, Alicja, et al.
Publicado: (2010)

Molecular signature of cell cycle exit induced in human T lymphoblasts by IL-2 withdrawal
por: Chechlinska, Magdalena, et al.
Publicado: (2009)

Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas
por: Moes-Sosnowska, Joanna, et al.
Publicado: (2019)

Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival
por: Krajewska, Jolanta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a28kbh1o8vj1n384dibkao7set